Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials
Top Cited Papers
Open Access
- 1 October 2013
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 31 (42), 4867-4873
- https://doi.org/10.1016/j.vaccine.2013.07.051
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trialVaccine, 2013
- Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis studyBMC Public Health, 2011
- Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnosticsProceedings of the National Academy of Sciences of the United States of America, 2009
- MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus MacaquesPLOS ONE, 2009
- TheMycobacterium tuberculosis phoPROperon Is Positively Autoregulated in the Virulent Strain H37RvJournal of Bacteriology, 2008
- Novel genome polymorphisms in BCG vaccine strains and impact on efficacyBMC Genomics, 2008
- Control of M. tuberculosis ESAT-6 Secretion and Specific T Cell Recognition by PhoPPLoS Pathogens, 2008
- Genome plasticity of BCG and impact on vaccine efficacyProceedings of the National Academy of Sciences of the United States of America, 2007
- Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strainClinical and Experimental Immunology, 2006
- The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigsVaccine, 2006